AbbVie Stock Will $300: Timing and Risks to Watch
AbbVie’s Q1 2026 results show strong immunology growth even as biosimilar challenges weigh on revenue. Analysts debat...
Compare SP 500 and diversified funds for retirement, highlighting cost, risk, and diversification benefits to guide your decision.
25,576 articlesAbbVie’s Q1 2026 results show strong immunology growth even as biosimilar challenges weigh on revenue. Analysts debat...
In the week ending June 12, 2026, mortgage applications slip 3.8% as purchase demand stays ahead of 2025, signaling a...
A decades‑long pause in U.S. nuclear construction has reshaped the investment landscape, rewarding a utility with a l...
META AI forecasts a potential XRP rally to multi-dollar levels by late-2026, hinging on regulatory clarity, network a...
Medicare's day-count cliffs push hospital costs $434 per day after day 60, rising to $868 per day after day 90. The p...
Bitcoin holds near the $64,000 level as major altcoins pause, pointing to a broader market consolidation. Ethereum si...
Bitcoin weakens as the dollar strengthens, signaling tighter liquidity and renewed selling pressure. Analysts warn th...
A Korea-led chip selloff pulled AMD and Intel lower while Nvidia slipped, prompting analysts to frame the move as hea...
Sunrun jumped on news of a large-scale virtual power plant deal with Tesla and Renew Home, signaling a shift in distr...
A long-time investor explains why AbbVie’s mix of rapidly growing immunology drugs and a dependable dividend keeps dr...
The Federal Reserve’s 2026 annual stress test finds the largest U.S. banks would weather a sharp downturn without fai...
Moscow has launched a limited, state-backed crypto settlement corridor for select foreign-trade partners, testing ho...